biotech / news / / Reuters
The FDA's Oncologic Drugs Advisory Committee (ODAC) voted six to three against camizestrant.
The FDA panel voted 6-3 against camizestrant due to concerns with its trial design, not efficacy.
KEY POINTS
- Analysts believe camizestrant could still gain FDA approval based on data from other studies.
- Bernstein lowered AstraZeneca's target price to 18,600 pence, citing limited immediate stock upside.
- Camizestrant represents only about 1% of AstraZeneca's overall valuation, per JPMorgan.
COMPANIES
Summarized by Newsio from Reuters. How we summarize →